Literature DB >> 22140056

Repeated transplantation of hepatocytes prevents fulminant hepatitis in a rat model of Wilson's disease.

Vanessa Sauer1, Ramsi Siaj, Sandra Stöppeler, Ralf Bahde, Hans-Ullrich Spiegel, Gabriele Köhler, Andree Zibert, Hartmut H J Schmidt.   

Abstract

The outcome of consecutive hepatocyte transplants was explored in a rat model of Wilson's disease before the onset of fulminant hepatitis without preconditioning regimens. Rats received a high-copper diet in order to induce a rapid induction of liver failure. Sham-operated rats (15/15) developed jaundice and fulminant hepatitis, and they died within 4 weeks of first transplantation. Despite the continuation of a high dietary copper challenge, long-term survival was observed for a notable proportion of the transplanted animals (7/18). All survivors displayed normalized levels of hepatitis-associated serum markers and ceruloplasmin oxidase activity by posttransplant days 50 and 98, respectively. The liver copper concentrations, the liver histology, and the expression of marker genes were significantly restored within 4 months of transplantation in comparison with the control group. The high expression of a copper transporter gene (ATPase Cu++ transporting beta polypeptide) in the livers of the survivors indicated a high rate of repopulation by donor hepatocytes. Our data suggest that repeated cell transplantation can overcome the limitations of a single therapy session in rats with severe hepatic disease by functionally restoring the host liver without preconditioning.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22140056     DOI: 10.1002/lt.22466

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  8 in total

1.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

Review 2.  Wilson disease-treatment perspectives.

Authors:  Tomasz Litwin; Karolina Dzieżyc; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 3.  Animal models of Wilson disease.

Authors:  Emily Reed; Svetlana Lutsenko; Oliver Bandmann
Journal:  J Neurochem       Date:  2018-06-26       Impact factor: 5.372

4.  CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson's disease.

Authors:  Rui Wei; Jiayin Yang; Chi-Wa Cheng; Wai-In Ho; Na Li; Yang Hu; Xueyu Hong; Jian Fu; Bo Yang; Yuqing Liu; Lixiang Jiang; Wing-Hon Lai; Ka-Wing Au; Wai-Ling Tsang; Yiu-Lam Tse; Kwong-Man Ng; Miguel A Esteban; Hung-Fat Tse
Journal:  JHEP Rep       Date:  2021-10-30

5.  Dietary copper triggers onset of fulminant hepatitis in the Long-Evans cinnamon rat model.

Authors:  Ramsi Siaj; Vanessa Sauer; Sandra Stöppeler; Hans-Ullrich Spiegel; Gabriele Köhler; Andree Zibert; Hartmut H J Schmidt
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

6.  Transplantation of ATP7B-transduced bone marrow mesenchymal stem cells decreases copper overload in rats.

Authors:  Shenglin Chen; Cunhua Shao; Tianfu Dong; Hao Chai; Xinkui Xiong; Daoyi Sun; Long Zhang; Yue Yu; Ping Wang; Feng Cheng
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

7.  Therapeutic potential of hepatocyte-like-cells converted from stem cells from human exfoliated deciduous teeth in fulminant Wilson's disease.

Authors:  Junko Fujiyoshi; Haruyoshi Yamaza; Soichiro Sonoda; Ratih Yuniartha; Kenji Ihara; Kazuaki Nonaka; Tomoaki Taguchi; Shouichi Ohga; Takayoshi Yamaza
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

8.  Longitudinal analysis of serum miR-122 in a rat model of Wilson's disease.

Authors:  Ramsi Siaj; Vanessa Sauer; Sandra Stöppeler; Joachim Gerß; Hans-Ullrich Spiegel; Gabriele Köhler; Andree Zibert; Hartmut H-J Schmidt
Journal:  Hepatol Int       Date:  2012-02-11       Impact factor: 6.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.